Dosing of first patient in Phase I trial of MEK inhibitor prompted a $2-million payment.



AstraZeneca dosed the first patient in a Phase I trial of Array BioPharma’s anticancer candidate. The milestone triggered a $2-million payment to Array BioPharma.


ARRY-704 (AZD8330) is potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. ARRY-704 has shown tumor suppressive activity in multiple preclinical models of human cancer, including melanoma, pancreatic, colon, lung, and breast cancers, according to Array BioPharma.


In December 2003, Array partnered the oncology portion of its MEK program for co-development and commercialization with AstraZeneca. The collaboration included R&D of additional clinical candidates, which resulted in the selection of ARRY-704 in December 2005.








This site uses Akismet to reduce spam. Learn how your comment data is processed.